An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Clinical trial NCT04770545 · COMPLETED
Trial details
- NCT number
- NCT04770545
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-04
- Primary completion
- 2025-09-05
- Enrollment
- 792
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.